标题
E2F1 inhibition mediates cell death of metastatic melanoma
作者
关键词
-
出版物
Cell Death & Disease
Volume 9, Issue 5, Pages -
出版商
Springer Nature
发表日期
2018-05-09
DOI
10.1038/s41419-018-0566-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
- (2017) Paola Falletta et al. GENES & DEVELOPMENT
- Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance
- (2016) Michaël Cerezo et al. CANCER CELL
- Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
- (2016) Antoine Millet et al. MEDICINAL RESEARCH REVIEWS
- Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue
- (2016) Florian Rouaud et al. Oncotarget
- Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
- (2015) Christian Posch et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
- (2015) Abdelali Lehraiki et al. Cell Discovery
- Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor
- (2015) Paola Corazao-Rozas et al. Oncotarget
- Inhibition of Melanogenesis by the Antidiabetic Metformin
- (2014) Abdelali Lehraiki et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
- (2013) Z. Ji et al. CLINICAL CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Cutaneous melanoma
- (2013) Alexander MM Eggermont et al. LANCET
- Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
- (2013) M. Cerezo et al. MOLECULAR CANCER THERAPEUTICS
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- The Dark Side of E2F1: In Transit beyond Apoptosis
- (2012) D. Engelmann et al. CANCER RESEARCH
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6
- (2012) Sameer Phalke et al. NUCLEIC ACIDS RESEARCH
- Cell cycle regulators in the control of metabolism
- (2011) Emilie Blanchet et al. CELL CYCLE
- E2F1-dependent oncogenic addiction of melanoma cells to MDM2
- (2011) M Verhaegen et al. ONCOGENE
- Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas
- (2010) Sandy Giuliano et al. CANCER RESEARCH
- Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth
- (2010) T Botton et al. CELL DEATH AND DIFFERENTIATION
- Feedback between p21 and reactive oxygen production is necessary for cell senescence
- (2010) João F Passos et al. Molecular Systems Biology
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone
- (2009) Thomas Botton et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- E2F1 in Melanoma Progression and Metastasis
- (2009) Vijay Alla et al. JNCI-Journal of the National Cancer Institute
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival
- (2009) D. Bogunovic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Small-Molecule E2F Inhibitor Blocks Growth in a Melanoma Culture Model
- (2008) Y. Ma et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More